Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of TRS005 in R/R CD20-positive B-NHL
NCT05395533Phase 1Active, not recruiting
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Start
- Sep 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TRS005 in B-cell non-Hodgkin lymphoma, sponsored by Zhejiang Teruisi Pharmaceutical Inc. Primary endpoints: Number of Participants With Dose-limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
TRS005
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05395533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395533.